We are
working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients

cell-1
cell-2
cell-3
cell-4
cell-5
cell-6

Pipeline

Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer.

PreclinicalClinicalMarketed
 IndicationProof of PrincipleSafetyDose OptimizationClinical ActivityPivotalCommercial
Heme Malignancies
Fimepinostat
HDAC/PI3K
MYC-altered cancers

FDA Fast Track Designation

CA-4948*
IRAK4
MYD88/TLR-altered DLBCL, WM

CA-4948*
IRAK4
IL-1R/TLR-altered AML, MDS

Immune Checkpoint Inhibitors
CA-170*
VISTA/PDL1
VISTA-expressing Cancers

CI-8993**
VISTA
VISTA-expressing Cancers

CA-327*
TIM3/PDL1
TIM3-expressing Cancers

Approved Drug
Erivedge***
Hedgehog
Basal Cell Carcinoma

DrugIndicationStage
Heme Malignancies
Fimepinostat
HDAC/PI3K
MYC-altered cancersClinical Activity
CA-4948*
IRAK4
MYD88/TLR-altered DLBCL, WMDose Optimization
CA-4948*
IRAK4
IL-1R/TLR-altered AML, MDSProof of Principle
Immune Checkpoint Inhibitors
CA-170*
VISTA/PDL1
VISTA-expressing CancersDose Optimization
CI-8993**
VISTA
VISTA-expressing CancersProof of Principle
CA-327*
TIM3/PDL1
TIM3-expressing CancersProof of Principle
Approved Drug
Erivedge***
Hedgehog
Basal Cell CarcinomaCommercial

* IP licensed from Aurigene
** IP licensed from ImmuNext
*** IP licensed to Genentech (Curis receives royalty income)